Topadur Pharma

News

8.10.20

Interview with Reto Naef, CEO of TOPADUR PHARMA AG

Read the full interview:

Download Document Dokument herunterladen Switzerland Global Enterprise Switzerland Global Enterprise

5.10.21

Press Release

TOPADUR Pharma AG announces positive results from TOP-N53 First-in-Human Study

TOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.

27.6.22

News

Scientific Publication in the International Journal of Molecular Sciences

A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Activates Autophagy in Primary Skin Fibroblasts.

7.9.23

News

TOPADUR has been selected as a TOP 100 Scale-up 2023 with unicorn potential

We are proud to be recognized as one of Switzerland's most promising scale-ups in 2023.